Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Elizabeth Greyber"'
Publikováno v:
Journal of General Internal Medicine. 21:363-366
To assess the effect of hormone therapy (HT) on coronary heart disease (CHD) events in younger and older postmenopausal women.A comprehensive database search identified randomized-controlled trials of HT of at least 6 months' duration that reported C
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4204f038da43e4ed340cc4d62589d2f7
https://doi.org/10.1111/j.1525-1497.2006.00389.x
https://doi.org/10.1111/j.1525-1497.2006.00389.x
Autor:
Thomas M. Ormiston, Shelley R. Salpeter, Elizabeth Greyber, Judith M. E. Walsh, Edwin E. Salpeter
Publikováno v:
Journal of General Internal Medicine. 19:791-804
OBJECTIVE To assess mortality associated with hormone replacement in younger and older postmenopausal women.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::62b74ecaccbb38a073ca73744d0b1d80
https://doi.org/10.1111/j.1525-1497.2004.30281.x
https://doi.org/10.1111/j.1525-1497.2004.30281.x
Publikováno v:
The Cochrane database of systematic reviews. (1)
Metformin is an oral anti-hyperglycemic agent that has been shown to reduce total mortality compared to other anti-hyperglycemic agents, in the treatment of type 2 diabetes mellitus. Metformin, however, is thought to increase the risk of lactic acido
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::2cd5d6669a040d96203d13b2be13704b
https://pubmed.ncbi.nlm.nih.gov/20643987
https://pubmed.ncbi.nlm.nih.gov/20643987
Publikováno v:
The Cochrane Library
Background Metformin is an oral anti-hyperglycemic agent that has been shown to reduce total mortality compared to other anti-hyperglycemic agents, in the treatment of type 2 diabetes mellitus. Metformin, however, is thought to increase the risk of l
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f9f3c979ae6acaec42ede6d9c2bce862
https://doi.org/10.1002/14651858.cd002967.pub3
https://doi.org/10.1002/14651858.cd002967.pub3
Autor:
N. S. Buckley, Edwin E. Salpeter, Elizabeth Greyber, Shelley R. Salpeter, Judith M. E. Walsh, Thomas M. Ormiston
Publikováno v:
Diabetes, obesitymetabolism. 8(5)
Aim: To quantify the effects of hormone-replacement therapy (HRT) on components of the metabolic syndrome in postmenopausal women. Methods: Comprehensive searches of electronic databases were performed from April 1966 to October 2004. We included ran
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::410c20110c727629b2fb9ccd1a6cbaa9
https://pubmed.ncbi.nlm.nih.gov/16918589
https://pubmed.ncbi.nlm.nih.gov/16918589
¿El tratamiento con metformina aumenta el riesgo de acidosis láctica en la diabetes mellitus tipo 2?
Autor:
Isabel Fernández Fernández, Elizabeth Greyber, Edwin E. Salpeter, Shelley R. Salpeter, G.A. Pasternak
Publikováno v:
FMC - Formación Médica Continuada en Atención Primaria. 11:355
Objetivo Evaluar el riesgo de acidosis lactica mortal y no mortal asociado con el uso de la metformina en pacientes con diabetes tipo 2 (Dm2), con relacion al placebo u otros tratamientos antidiabeticos. Valorar los indices de lactato en sangre antes
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c19f4e5d521421f2b46b8791e45de18e
https://doi.org/10.1016/s1134-2072(04)76141-1
https://doi.org/10.1016/s1134-2072(04)76141-1
Publikováno v:
Archives of Internal Medicine. 163:2594
Background: Metformin therapy for type 2 diabetes mellitus has been shown to reduce total mortality rates compared with other antihyperglycemic treatments but is thought to increase the risk of lactic acidosis. The true incidence of fatal and nonfata
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e4c99b26e507f878c32e43310d486ea7
https://doi.org/10.1001/archinte.163.21.2594
https://doi.org/10.1001/archinte.163.21.2594